Home » Astrazeneca, vaccines push the accounts: sales up 31%

Astrazeneca, vaccines push the accounts: sales up 31%

by admin

In the first half of the year, AstraZeneca recorded revenue growth of 23% to $ 15.540 billion; in the second quarter alone, sales increased 31% to $ 8.220 billion. Excluding the contribution of the Covid-19 pandemic vaccine, revenue grew by 14% in the first half and 17% in the quarter. Factors such as the recent acquisition of Alexion Pharmaceuticals support the company’s transition to long-term sustainable growth.

«Astrazeneca – said the managing director Pascal Soriot – has had another period of strong growth thanks to solid performances in all regions and areas. As a result, we have achieved a further increase in profits, supported the launches in progress and continued our investment in research and development ». In particular, Alexion «will allow us to improve our pipeline, extending the company’s presence in rare diseases and immunology. After the successful acquisition of Alexion, today we update our guidance for the full year 2021; our long-term goals to accelerate scientific discovery, invest in sustainable growth and deliver greater patient benefits remain unchanged. ”

Sanofi also did well, raising its forecasts for 2021, after a solid second quarter: net profit fell to 1.21 billion (7.6 the year before), due to the sale of Regeneron last year, but the sales are dynamic. Driven by vaccines and the flagship product Dupixent, revenue rose 6.5% to 8.7 billion, a figure in line with analysts’ expectations. The targets for the current year see earnings per share up 12% at constant exchange rates, after reaching 1.38 euros in the second quarter, up almost 8%. Among the divisions: the specialist medicines branch recorded + 14% to over 3 billion, supported by Dupixent (+ 45% to 1.2 billion) for atopic dermatitis and asthma; vaccines + 10% to 1 billion, mainly thanks to those against meningitis; in general medicine (diabetes, cardiovascular) sales remained stable at 3.5 billion; consumer health revenue (including doliprane) rose more than 6% to 1 billion.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy